首页> 外文OA文献 >Beyond rituximab maintenance. relapsing follicular lymphoma during or after end of rituximab maintenance: analysis of Czech Lymphoma Study Group (CLSG) database

【2h】

Beyond rituximab maintenance. relapsing follicular lymphoma during or after end of rituximab maintenance: analysis of Czech Lymphoma Study Group (CLSG) database

机译：超越rituximab维护。在Rituximab维护期间或之后复发滤泡淋巴瘤：捷克淋巴瘤研究组（CLSG）数据库分析

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
A. Janikova; V. Campr; N. Kopalova; K. Benesova; D. Belada; V. Prochazka; J. Duras; J. Dlouha; H. Mocikova; A. Sykorova; M. Brejcha; J. Mayer; M. Trneny;
展开▼
作者单位

展开▼
年度 2017
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. 复发性晚期滤泡性淋巴瘤的IDEC-C2B8(利妥希玛)抗CD20抗体治疗:德国低度恶性淋巴瘤研究组Ⅱ期研究结果 [J] . 李登举, 唐锦治中德临床肿瘤学杂志（英文版） . 2001,第004期
2. Impact of rituximab maintenance and maintenance schedule on prognosis in first-line treatment of follicular lymphoma. Retrospective analysis from Czech Lymphoma Study Group (CLSG) database [J] . Janikova Andrea, Bortlicek Zbynek, Campr Vit, Leukemia and lymphoma . 2016,第5期

机译：利妥昔单抗维持和维持时间表对滤泡性淋巴瘤一线治疗预后的影响。捷克淋巴瘤研究小组（CLSG）数据库的回顾性分析
3. The incidence of biopsy-proven transformation in follicular lymphoma in the rituximab era. A retrospective analysis from the Czech Lymphoma Study Group (CLSG) database [J] . Andrea Janikova, Zbynek Bortlicek, Vit Campr, Annals of hematology . 2018,第4期

机译：中毒素时代滤泡淋巴瘤活检证实转化的发病率。捷克淋巴瘤研究组（CLSG）数据库的回顾性分析
4. The influence of maintenance therapy of rituximab on the survival of elderly patients with follicular lymphoma. A retrospective analysis from the database of the Czech Lymphoma Study Group [J] . Belada David, Prochazka Vit, Janikova Andrea, Leukemia Research: A Forum for Studies on Leukemia and Normal Hemopoiesis . 2018,第期

机译：利妥昔单抗维持治疗对老年卵泡淋巴瘤患者存活的影响。捷克淋巴瘤研究组数据库的回顾性分析
5. Characterization of a rituximab variant with potent antitumor activity against rituximab-resistant B-cell lymphoma [C] . Bohua Li, Hao Wang, Yajun Guo, International conference of molecular simulations and applied informatics technologies . 2012

机译：具有抗利妥昔单抗的B细胞淋巴瘤的有效抗肿瘤活性的利妥昔单抗变体的表征
6. Safety and Efficacy of the Immunomodulatory Drug (IMiD) Lenalidomide in Patients with Lymphoma: Development of RU051417I - Phase I/II Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) with Lenalidomide [R2-ICE] in Patients with First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL). [D] . Kasi, Pashtoon Murtaza. 2018

机译：免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性：RU051417I-R-ICE（利妥昔单抗-异环磷酰胺-卡铂-依托泊苷）与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤（DLBCL）。
7. Bortezomib plus rituximab versus rituximab in patients with high-risk relapsed rituximab-naïve or rituximab-sensitive follicular lymphoma: subgroup analysis of a randomized phase 3 trial [O] . Pier Luigi Zinzani, Nuriet K Khuageva, Huaqing Wang, 2012

机译：硼替佐米联合利妥昔单抗与利妥昔单抗治疗高危复发未接受利妥昔单抗或利妥昔单抗敏感的滤泡性淋巴瘤的患者：一项3期随机试验的亚组分析
8. Phase II study of bortezomib in combination with rituximab, cyclophosphamide and prednisone with or without doxorubicin followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma [O] . Michael Craig, Wahid T. Hanna, Fernando Cabanillas, 2014

机译：二氮素与利妥昔单抗，环磷酰胺和泼尼松组合的II期研究，其中有或没有多柔比星，在复发或难治性滤泡淋巴瘤的患者中进行rituximab维持

Beyond rituximab maintenance. relapsing follicular lymphoma during or after end of rituximab maintenance: analysis of Czech Lymphoma Study Group (CLSG) database

著录项

引文网络

相似文献

相关主题

期刊订阅